StockData
YDESNasdaqServices-Medical LaboratoriesFiscal year ends December 31Also trades as YDESW

YD Bio Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026
$6.12+0.20 (+3.38%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

Ownership

Who owns YD Bio's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
3 buys · 0 sales
Net bought $128.53K

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Ethan Shen54,345,01177.06%13G (passive) amendmentFeb 17, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Ethan Shen PhDCEO, Director54,379,189Sep 16, 2026
Bo-Xiang ZhangChief Medical Officer, Director31,141Mar 27, 2026
Man Edmund HenChief Financial Officer–Mar 26, 2026
Kochi ChangDirector7,830Jul 1, 2026
Shao-Ta LuDirector58,981Jul 1, 2026
Jerry Yin-Chia LeeDirector–Mar 30, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Ethan Shen PhD
CEO, Director
Sep 14, 2026Buy+12,700$3.85$48.90K11,258,331
Ethan Shen PhD
CEO, Director
Sep 9, 2026Buy+3,100$3.93$12.18K11,245,631
Ethan Shen PhD
CEO, Director
Sep 4, 2026Buy+18,378$3.67$67.45K11,242,531
Shao-Ta Lu
Director
Jun 30, 2026Option exercise+5,749––7,830
Kochi Chang
Director
Jun 30, 2026Option exercise+5,749––7,830
Shao-Ta Lu
Director
Mar 31, 2026Option exercise+2,081––2,081
Kochi Chang
Director
Mar 31, 2026Option exercise+2,081––2,081

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.